PRESS RELEASE published on 04/14/2025 at 12:30, 11 months 12 days ago Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak NanoViricides, Inc. commences evaluation of clinical drug NV-387 for Measles virus treatment, utilizing innovative nanomedicine technology. Company aims to combat Measles outbreak and provide effective antiviral solution NanoViricides NV-387 Antiviral Nanomedicine Measles
BRIEF published on 03/11/2025 at 11:35, 1 year ago NanoViricides Sees Long-Term Potential Amid Stock Decline NV-387 Stock Market Antiviral Drugs Phase II Trial Tariff Policies
BRIEF published on 03/11/2025 at 11:35, 1 year ago NanoViricides voit un potentiel à long terme malgré la baisse des actions NV-387 Bourse Essai De Phase II Médicaments Antiviraux Politiques Tarifaires
PRESS RELEASE published on 03/11/2025 at 11:30, 1 year ago NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company NanoViricides, Inc. declares its business is not affected by US tariff policies or spending cuts, focusing on developing broad-spectrum antiviral drugs. The company's NV-387 shows potential for treating measles NanoViricides NV-387 Antiviral Drugs Measles Treatment Pandemic Solutions
BRIEF published on 03/04/2025 at 12:35, 1 year ago Measles Crisis: NanoViricides Proposes NV-387 as Potential Solution NV-387 Public Health Clinical Trials Antiviral Treatment Measles Outbreak
BRIEF published on 03/04/2025 at 12:35, 1 year ago Crise de la rougeole : NanoViricides propose le NV-387 comme solution potentielle NV-387 Essais Cliniques Santé Publique Traitement Antiviral Épidémie De Rougeole
PRESS RELEASE published on 03/04/2025 at 12:30, 1 year ago Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan HHS Secretary Robert F. Kennedy Jr. discusses urgent need for antiviral treatment in FoxNews Op-Ed amidst measles outbreak, highlighting potential of NanoViricides' NV-387 drug Robert F. Kennedy Jr. Antiviral Treatment Measles Outbreak HHS Secretary NanoViricides NV-387
BRIEF published on 02/19/2025 at 12:35, 1 year 1 month ago NanoViricides Reports Q4 2024 Financials and NV-387 Clinical Trials Progress NanoViricides NV-387 Clinical Trials Financial Reports Antiviral Development
BRIEF published on 02/19/2025 at 12:35, 1 year 1 month ago NanoViricides publie ses résultats financiers du quatrième trimestre 2024 et les progrès des essais cliniques sur le NV-387 NanoViricides NV-387 Essais Cliniques Rapports Financiers Développement D'antiviraux
PRESS RELEASE published on 02/19/2025 at 12:30, 1 year 1 month ago NanoViricides, Inc. Has Filed its Quarterly Report NanoViricides, Inc. prepares for Phase II clinical trials of broad-spectrum antiviral NV-387, focused on MPox pandemic and Bird Flu, with strong financials and innovative drug strategy NanoViricides NV-387 Phase II Trial Mpox Bird Flu
Published on 03/26/2026 at 23:00, 38 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 1 hour 33 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 1 hour 38 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 1 hour 38 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 2 hours 38 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 20:48, 2 hours 49 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 4 hours 17 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 4 hours 28 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 4 hours 28 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 5 hours 21 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 5 hours 21 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 5 hours 38 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 5 hours 38 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité